Head-to-head · WeighScore
Gala Health vs Teleios Health
The verdict
Gala Health takes it — 82.9/100 to 60.2/100.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Gala Health | Teleios Health |
|---|---|---|
| WeighScore | 82.9/100 | 60.2/100 |
| Grade | B− | C |
| Scorecard rank | #17 | #327 |
| Semaglutide | Not disclosed | $99/mo (starting dose, compounded) |
| Tirzepatide | $179/mo (yearly subscription) | $139/mo (starting dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #17 · B−
Strengths
- Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
- Prices are published openly rather than quiz-gated, with all doses included at the one rate
- All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet — injection only
- Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
Graded #327 · C
Strengths
- Compounded semaglutide from $99/mo — among the lowest floor prices in cash-pay telehealth
- Compounded tirzepatide from a competitive $139/mo floor
- Markets physician (MD/DO) prescribing rather than an NP-only model
- Clean meta-tag and SEO implementation
Where it loses points
- Single-page app: state availability, pharmacy partner, dose pricing, lab requirements, and refund policy aren't visible and couldn't be verified
- No named medical director, physician, or corporate entity disclosed
- Year founded unknown — a newer floor-price entrant warranting extra scrutiny
- No LegitScript, NABP, or SOC 2 trust signal found
- Heavy paid-acquisition ad-tech stack — pair with diligence on the clinical layer
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.